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Background
We conducted a review of cardiovascular magnetic reso-
nance studies performed in patients with Anderson-Fabry
disease (AFD) at our institution aiming to describe the
spectrum of imaging findings in this rare disease.
Methods
All patients with confirmed AFD who had cardiac MRI
at our center were included. Short-axis steady state free
precession cines and segmented inversion recovery late
gadolinium enhancement (LGE) images were acquired
using standard parameters. Offline analysis was per-
formed for LV volumes and maximum end-diastolic
wall thickness (EDWTmax). Patients were categorized
into 4 groups: 1) no wall thickening (EDWT≤12mm);
2) concentric hypertrophy (EDWTmax>12mm with sep-
tal to lateral wall thickness ratio <1.3); 3) asymmetric
hypertrophy (EDWTmax >12mm with septal to lateral
wall thickness ratio ≥1.3); and 4) apical hypertrophy.
LGE was quantified using a semi-automated technique
with thresholds of 2SD, 4SD and 6SD. Charts were
reviewed for clinical information.
Results
Forty-one patients were included (53.6% male, n=22),
median age 45.3 years (range 22.3-68.1). Morphological
MR findings are summarized in Table 1. Males were
more likely to have increased LV wall thickness and LV
mass. The 4-SD threshold for LGE demonstrated the
best agreement with manual threshold quantification
(k=0.62). 6-SD and 2-SD demonstrated lower agreement
with manual threshold quantification k=0.55 and k=0.05
respectively.
Just over two thirds of patients had late gadolinium
enhancement (LGE), but only half of these had typical
lateral wall mid-myocardial scar. Only a quarter of
patients had both concentric wall thickening and typical
lateral wall scar. Only 11 of 25 patients with wall thick-
ening had elevated LVMI. There was significantly more
myocardial scar (as a percentage of total myocardium)
in patients with elevated LVMI (n=10, 10.97%, IQR
7.57-17.43%) than in patients with normal LVMI (n=19,
1.87%, IQR 1.15-4.37%, p<0.001), and significantly more
scar in patients with wall thickening (n=21, 7.1%, IQR
2.35-11.71%) than those without wall thickening(n=8,
1.19%, IQR 0.83-2.23%, p=0.003). Patients with elevated
LVMI had higher incidence of arrhythmia (atrial fibrilla-
tion & ventricular tachycardia[VT]) than those without
elevated LVMI (8/13 vs. 3/28, p=0.001). Patients with
elevated LVMI had higher incidence of VT than those
without elevated LVMI (4/13 vs. 1/28, p=0.028).
Conclusions
Concentric thickening and lateral wall mid-myocardial
scar are the most common manifestations of AFD, but
the spectrum includes cases identical to apical and
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Age (years) 47.4 (36.5-55.5) 44.9 (34.9-
60.8)
0.896
Extracardiac involvement 21 (95.5%) 15 (78.9%) 0.164
Prior enzyme replacement therapy 17 (77.3%) 11 (57.9%) 0.313
EDWTmax (mm) 14.6 (13.2-17.2) 11.6 (8.9-13.5) 0.013
No wall thickening 4 (18.2%) 12 (63.2%) 0.005
Concentric hypertrophy 14 (63.6%) 5 (26.3%) 0.027
Asymmetric septal hypertrophy 3 (13.6%) 1 (5.3%) 0.610
Apical hypertrophy 1 (4.5%) 1 (5.3%) 1.000
LV ejection fraction (%) 58.3 (54.2-63.0) 60.4 (57.3-
65.6)
0.200





LV mass index (g/m2) 78.0 (64.8-94.7) 56.7 (51.5-
63.0)
0.001
Elevated LV mass index 9 (40.9%) 4 (21.1%) 0.200
Myocardial scar 16 (72.7%) 13 (68.4%) 1.000
Typical midwall lateral wall scar 6 (27.3%) 8 (42.1%) 0.346
Patients with concentric hypertrophy and typical midwall lateral wall scar 5 (22.7%) 4 (21.1%) 1.000
Patients with concentric hypertrophy and typical midwall lateral wall scar
Scar as percentage of total myocardium at 4SD calculated from 16 males and 13 females with myocardial
scar (%)
4.9 (2.0-10.8) 1.9 (1.2-10.2) 0.381
Age is presented as median (range). All other continuous variables were compared with a Mann-Whitney Rank Sum test and presented as median (interquartile
range). Categorical variables were compared with a Fisher test.
Figure 1 A-B. 63 year old female with Anderson-Fabry Disease on enzyme replacement therapy and a history of ventricular tachycardia. CMR
reveals an apical pattern of hypertrophy and apical scar. C-D. 58 year old male with Anderson-Fabry Disease on enzyme replacement therapy.
CMR reveals reverse septal curvature subtype of asymmetric septal hypertrophy and predominantly hinge point scar
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